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MANUFACTURING STRATEGY
AND NEW VENTURE PERFORMANCE:
A COMPARISON OF INDEPENDENT
AND CORPORATE VENTURES IN
THE BIOTECHNOLOGY INDUSTRY
SHAKER A. ZAHRA, GERARD GEORGE
Georgia State University, Syracuse University
Little empirical research has compared the manufacturing strategies of corporate
and independent new ventures. This study explores these differences with data
from the young, science-based biotechnology industry, and examines the perfor-
mance effects of manufacturing strategy variables including scope, competitive
thrust, and capabilities. The results show that the corporate and independent
biotechnology new ventures pursue significantly different manufacturing strate-
gies, and that different dimensions of manufacturing strategies affect the perfor-
mance of corporate vs. independent ventures quite differently.  2000 Elsevier
Science Inc.
INTRODUCTION
New ventures play a major role in the creation and growth of high technology
industries. These young organizations usually succeed by transforming scientific
discoveries into innovative product and process technologies that meet customer
needs. New ventures, whether established by independent entrepreneurs or corpora-
tions, must develop a wide range of capabilities in order to capitalize on the opportu-
nities that exist in their industries (Chaston & Mangles 1997; Roberts 1991). In
particular, new ventures need to develop or acquire excellent manufacturing capabil-
ities that transform their innovations into products and goods (Berry & Cooper
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1999; Hamilton, Vila & Dibner 1990), build market share, ensure survival, lead
to sales growth, and achieve profitability (Marino & DeNoble 1997; Pisano &
Wheelwright 1995). Consequently, building strong manufacturing capabilities is
considered among the most important challenges for managers of technology-based
ventures (Hamilton & Singh 1992; Kazanjian & Drazin 1990). Developing these
capabilities can be achieved by acquiring modern production technologies and
gaining the skills that ensure the superiority of the ventures’ products (Carey et
al., 1997; Keeley & Roure 1990). According to Pisano and Wheelwright (1995),
the lack of effective manufacturing capabilities has led to delays in new product
development and introductions, and resulted in lower company performance among
some high technology companies, especially in the biotechnology industry.
The resource-based theory of the firm (Penrose 1959; Grant 1995; Teece, Pisano, &
Shuen 1997) suggests that success in today’s markets goes to firms that have achieved
and nurtured effective capabilities through sustained investments in acquiring rele-
vant assets, resources, and skills (Grant 1995). To succeed in building viable manu-
facturing capabilities, new ventures also need to develop effective manufacturing
strategies (Minor, Hensley, & Wood 1994). The content of these strategies specifies
new ventures’ manufacturing goals and strategic priorities, the scope of their opera-
tions, and competitive approaches (Bantel 1997; Ettlie & Penner-Hahn 1994; Gar-
rone & Rossini 1998). Currently, research on the content of the manufacturing
strategies in high technology new ventures is in its infancy and little is known about
the differences in manufacturing strategies that exist between ventures created by
entrepreneurs and those developed by corporations.
This study examines the differences in manufacturing strategies between new
ventures established by corporations (hereafter “corporate ventures” or CVs) and
those founded by independent entrepreneurs (hereafter “independent ventures” or
IVs). The study also explores the relationships between the manufacturing strategy
variables and key indicators of new venture performance (NVP), including innova-
tive outputs (i.e., patents). We address these two issues in the context of the dynamic
U.S. biotechnology industry where both CVs and IVs struggle for survival. Given
that the industry represents a major scientific paradigm shift, traditional prescrip-
tions about effective manufacturing strategies may not be useful for biotechnology
ventures. Most prior research on manufacturing strategies has been conducted in
established companies (e.g., Anderson, Cleveland, & Schroeder 1989; Vickery,
Droge, & Markland 1993) but new ventures that lack the resources and therefore
cannot copy strategic choices of established firms. Further, given that IVs and CVs
battle each other for market share, identifying the differences that might exist in
the content of their manufacturing strategies can clarify a source of variation in
their financial performance. The study, therefore, responds to calls for empirical
research that determines the sources of differences in NVP by exploring the effect
of CVs’ and IVs’ manufacturing strategies on performance (McCann, 1991), and by
using multiple measures of new venture financial (Minor et al., 1994) and innovative
performance (patents).
The study also explores the impact of manufacturing strategies on NVP using a
sample of biotechnology ventures, one of the key industries of the future (Shan &
Song, 1997). This industry has enriched the lives of more than 100 million people
with nearly 40 drugs that have already been approved by the Food & Drug Adminis-
tration (FDA). With market capitalization of $83 billion and high-value job creation
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of 118,000 in the U.S. alone, the biotechnology industry has potential to revolutionize
research and product development in several other industries such as human thera-
peutics, agriculture, veterinary sciences and environmental sciences, among others
(BIO 1998). To date, research on the biotechnology industry has focused on examin-
ing the effects of strategic characteristics (Liebeskind et al., 1996; Powell, Koput, &
Smith-Doerr 1996), institutional linkages, alliance patterns (Deeds & Hill, 1996), and
R&D activities (Pisano 1990; Shan et al., 1994). However, the role of manufacturing
capabilities as an important strategic tool within this industry has been largely
ignored. This study is one step toward understanding the manufacturing strategies
used in this industry.
The next section of the paper presents the study’s theoretical background and
hypotheses, emphasizing the anticipated differences between CVs and IVs in their
respective manufacturing strategies. The expected associations of manufacturing
strategies and the performance of biotechnology CVs and IVs are then discussed.
Next, an empirical study that tests the hypotheses is summarized. The paper con-
cludes by discussing the results and their implications for managerial practice and
future research on the manufacturing strategies of both CVs and IVs.
THEORY AND HYPOTHESES
Research on the determinants of NVP suggests that a venture’s external environ-
ment, competitive strategy, internal organization and culture, and capabilities influ-
ence its performance (Carter et al., 1994). Consequently, researchers have studied
the strategies new ventures use in developing strong capabilities that lead to superior
performance (McGrath, Venkataraman, & MacMillan, 1994), measured by profit-
ability and growth (Chaston & Mangles, 1997; Thayer, 1995).
The resource-based theory of the firm (Grant, 1995) posits that competitive
advantage designed around a strong set of capabilities is essential for achieving
superior NVP (McGrath et al., 1994; Teece et al., 1997; Pisano & Wheelwright, 1995).
Strong manufacturing capabilities can give a new venture a significant competitive
advantage. These capabilities are the skills and competencies a venture gains from
its manufacturing assets, resources (both tangible and intangible), knowledge, and
experience (Teece et al., 1997). When manufacturing capabilities are embedded in
the venture’s culture and systems, they become difficult for competitors to decipher
or imitate (Grant 1995), thus protecting the firm’s competitive advantage.
Manufacturing is one of the key areas where a venture can develop strong
capabilities that become the foundation of successful market performance (Berry &
Cooper, 1999; Teece et al., 1997; Vos & Allegra, 1998; Zahra & Das, 1993). One
reason is that information on the venture’s manufacturing operations are usually
difficult for competitors to gather, which can reduce imitation by the firm’s rivals.
These operations also benefit from, and contribute to, the venture’s other functional
activities (e.g., product design) and lead to higher NVP (Chaston & Mangles, 1997).
The learning gained within manufacturing operations can also revise and redefine
the venture’s product portfolio and its competitive approach. An effective strategy
ensures that manufacturing operations’ priorities and capabilities are consistent
with the venture’s mission (Leong & Ward, 1995).
Considerable effort has been devoted to studying manufacturing strategy and
316 THE JOURNAL OF HIGH TECHNOLOGY MANAGEMENT RESEARCH VOL. 10/ NO. 2/1999
its impact on a company’s performance (Ettlie & Penner-Hahn, 1994). Yet, little
attention has been given to the content of the new ventures’ manufacturing strategies
in high technology industries, the focus of this paper. Pisano and Wheelwright (1995:
93) warn that, “Few managers of high-technology companies view manufacturing as
a primary source of competitive advantage.” This thinking can undermine the
profitability and survival of young companies.
Little is known about the differences in the content of manufacturing strategies
followed by different types of new ventures within the same industry. To fill this gap
in the literature, this paper examines the potential differences in the manufacturing
strategies of CVs versus IVs. The paper proposes that differences in resources and
capabilities can explain the variations in the manufacturing strategies used by CVs
and IVs (McDougall, Deane, & D’Souza, 1992). As indicated in Table 1, CVs
typically benefit from having access to their sponsors’ financial resources, distribu-
tion channels, marketing expertise, existing technologies, and manufacturing facili-
ties (Block & MacMillan, 1993). CVs usually rely on the sponsors’ “deep pockets”
in financing their strategies that emphasize the pursuit of a broadly defined market
(MacMillan & Day, 1987). Corporate sponsors often view investments in CVs as
worthwhile because they may create new markets, offer a window into emerging
technologies, or increase their sponsors’ ability to achieve growth and profitability
(Table 1).
The IVs’ resources are frequently more constrained than those of CVs, because
IVs primarily obtain resources from their owners and venture capitalists. While the
IVs’ access to financial resources might be limited, these firms benefit from their
owners’ direct and active involvement in the decision-making process. Owners and
venture capitalists’ insights, experience and long-term orientation are important
assets for IVs (Shrader & Simon, 1997). The owners’ incentives are also usually
closely aligned with those of the firm, because the ventures’ success creates wealth
for their owners and investors. Owners will work hard to develop the capabilities
needed for the IVs’ success. With significant prior research and training in the
biotechnology industry, these owners are also connected to important sources of
knowledge and capital in the industry, which can ease the transfer of best skills
into the IVs’ operations (Roberts, 1991). Further, the IVs’ flexible and lean organiza-
tional structures also allow these firms to move quickly to capitalize on opportunities
in their industry–whether in developing products or adopting new technologies. In
turn, this speed helps in penetrating new markets (Neven, Summe, & Uttal, 1990).
Companies organize and manage their CVs quite differently (Block & MacMillan,
1993), a factor that makes it difficult to generalize about these firms. The information
provided in Table 1 suggests that CVs and IVs face different challenges and benefit
from different capabilities. Though these factors can influence the strategic choices
CVs and IVs make, we know very little about their direct effect on these ventures’
manufacturing strategies. However, one previous study suggested that CVs and
IVs’ differences in the goals and resources can lead to significant variations in these
firms’ respective manufacturing strategies (McDougall et al., 1992). The following
section predicts the expected differences in CVs’ and IVs’ manufacturing strategies.
Manufacturing Strategy Variables in CVs versus IVs
CVs and IVs need to develop manufacturing strategies that allow them to build
capabilities that ensure success. Manufacturing strategy embodies the process and
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content of the choices made by a new venture to use its manufacturing capabilities
to achieve superior performance. The process component of manufacturing strategy
usually defines how a company develops or acquires the necessary manufacturing
capabilities, coordinates its operations, and deploys its manufacturing capabilities
to achieve superior performance (Ettlie & Penner-Hahn, 1994). The content of
manufacturing strategy defines the scope, goals, and competitive approaches used
in manufacturing operations to gain superior performance in a firm’s markets. This
paper focuses on the content of manufacturing strategies.
The strategic management (Andrews, 1971; Fahey & Christensen, 1986) and the
manufacturing strategy literatures (Leong & Ward, 1995; Minor et al., 1994) high-
light three key dimensions of the content of a firm’s strategy: (a) the scope of
manufacturing operations (the breadth of product lines); (b) the goals and competi-
tive thrusts of manufacturing operations (product uniqueness, product innovation,
quality, and low cost); and (c) the approaches and sources of manufacturing capabili-
ties (vertical integration, capital spending, and external sourcing). Scope defines
where a firm intends to exploit its manufacturing assets, resources and capabilities.
The goals and competitive approaches establish the priorities for a new venture’s
manufacturing operations in pursuit of superior performance in chosen markets.
Finally, the competitive approaches and sources dimension defines how a venture
will use its manufacturing capabilities to achieve its competitive goals and priorities.
Thus, while industry structure, regulatory forces and financing practices may affect
NVP, the scope, goals, and competitive approaches followed by new ventures in
their manufacturing operations can yielded additional performance benefits (higher
NVP), as would be suggested by both the resource-based and strategic choice
perspectives (Grant, 1995).
Manufacturing Scope. A venture’s emphasis on offering products to its markets
is an important component of its manufacturing strategy (Buzzell & Gale, 1987).
This emphasis is clarified in the choice of the product line breadth, which determines
the scope of a firm’s manufacturing operations. Product line breadth impacts the
venture’s ability to meet customer needs and achieve economies of scale, and
consequently, cost and pricing structures (Bantel, 1997). The choice of product line
breadth, therefore, depends on a firm’s resources that can be used to develop
manufacturing capabilities. In some industries, manufacturing a broad product line
leads to a higher market share and increased profitability, without increasing produc-
tion costs (Berry & Cooper, 1999; Kekre & Srinivasan, 1990). Thus, a venture can
leverage its manufacturing capabilities over a broader market. Presently, little is
known about how the CVs and IVs define the scope of their manufacturing operations.
CVs usually compete in a broadly defined market by serving multiple customer
groups with different needs (Hofer & Sandberg, 1987). Therefore, CVs are expected
to manufacture a broader product portfolio than IVs. The CVs’ access to greater
resources usually allows them “to enter the market in a bigger way than IVs”
(McDougall et al., 1992, p. 65). In fact, these authors found that CVs have broader
product lines than their IV counterparts, which supports Biggadike’s (1976) conclu-
sion that aggressive CVs that enter their markets on a large scale are more likely
to succeed than their rivals. MacMillan and Day (1987) also found that aggressive
CVs–defined as those ventures that serve a large market–are more successful than
their competitors.
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Given their access to the sponsors’ various resources (Table 1), CVs are expected
to follow a strategy of aggressive entry by targeting a large market and offering a
broad product line (Block & MacMillan, 1993). This expectation is reinforced by
Shan, Walker and Kogut’s (1994) finding of a positive relationship between areas
of research (i.e., diversity of subfields) and innovative outputs such as the number
of new products and patents. Clearly, some CVs may find it useful to enter a broad
market. However, it should be noted that Shan and colleagues did not consider
product breadth nor did they distinguish between CVs and IVs. Given that a single
biotechnology product can have multiple applications, some new ventures may not
develop different, multiple product lines. Instead, new ventures might focus on
developing more applications of the same products, thereby reducing the costs of
R&D and manufacturing while deepening their expertise. Also, the dynamism of
the biotechnology industry and the uncertainty of its future growth may reduce the
payoff from having a broad product line. Some biotechnology firms have been
unable to commercialize their products, raising a question about the desirability of
having a broad product line. However, the above observations suggest the following
hypothesis:
H1: CVs will manufacture broader product lines more than IVs.
The Goals and Competitive Thrust of Manufacturing Operations. Theoretically,
new ventures can use their manufacturing capabilities to achieve an array of competi-
tive priorities and objectives. Differences in these goals can lead to significant
variations in the competitive priorities assigned to the ventures’ manufacturing
operations. These priorities typically include new product innovation, quality, or
low cost manufacturing, as discussed below.
Product Innovation and Uniqueness. New ventures need to offer highly differ-
entiated products to distinguish themselves from established companies (Bell &
McNamara, 1991), especially in the early years of an emerging industry such as
biotechnology (Pisano & Wheelwright, 1995). Biotechnology ventures, therefore,
can use their manufacturing resources to develop those capabilities that allow them
to create and introduce differentiated products and gain market share (Grant,
1995). Researchers stress the importance of new products for achieving high NVP
(Keeley & Roure, 1993; Robinson, 1990). Hamilton et al., (1990) also suggest
product innovation can contribute significantly and positively to the success of
biotechnology companies. Product innovation influences a venture’s product designs
and content and determines the timing of their introductions (Wheelwright & Clark,
1992), which impacts market success (Carter et al., 1994). Researchers (e.g., Pisano &
Wheelwright, 1997) have suggested that product innovation is a key source of high
performance among biotechnology companies.
This study expects IVs to focus their resources on developing those manufacturing
capabilities that promote specialized products. Instead of blanketing the markets
with numerous products, IVs will selectively develop differentiated products with
high profit margins. This strategy is compatible with the niche orientation IVs
use. This orientation helps them avoid extending themselves beyond their core
capabilities while avoiding head-to-head competition with established rivals. Manu-
facturing differentiated products is also compatible with IVs’ founders’ and owners’
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significant R&D experience. Consequently, these founders emphasize developing
innovative products and will make this a priority in their manufacturing operations
(McDougall et al., 1992; Shrader & Simon, 1997). The IVs’ limited resources will
constrain the number of their new products.
CVs are expected to develop more new products than IVs, probably because
CVs typically target more customer groups than IVs. Further, as noted earlier, CVs
usually have access through their sponsors to the major engineering, marketing,
organizational and financial skills required for product innovation. Access to these
capabilities can enhance the CVs’ ability to develop new products. Therefore:
H2: CVs will emphasize product innovation in their manufacturing
strategy more than IVs.
Manufacturing for Product (Technology) Commercialization. Commercializing
new products is among the biotechnology industry’s most important challenges
(Carey et al., 1997). Commercialization centers upon quickly transferring a product
(technology) from the venture’s R&D lab to the market. Even though the speed
of product commercialization in the biotechnology industry depends significantly
on the regulations that govern clinical trials, it also depends on having an appropriate
organizational structure, maintaining close ties with customers and suppliers, and
gaining access to appropriate distribution channels (Burrill & Lee, 1992).
Manufacturing capabilities, in particular, can be used to accelerate the commer-
cialization of the venture’s products (Berry & Cooper, 1999), thus generating the
revenues and capital necessary for a firm’s survival. Voss and Allegra (1998) note
that the time to new product approvals has been shortened due to regulatory
reforms. Faster approvals will pressure companies to have appropriate manufactur-
ing capabilities in place to quickly introduce their products to the market. Biotech-
nology companies are also likely to face more intensive competition from rivals
who are eager to imitate their products and should have the manufacturing capabili-
ties needed to respond to these challenges. Commercialization depends also on the
ventures’ success in process innovations and having the manufacturing systems
necessary to develop complex designs. Manufacturing capabilities, therefore, can
determine the success of the new venture’s product innovations (Pisano & Wheel-
wright, 1995).
Given that CVs have access to their sponsors’ established distribution channels,
and marketing and production resources (McGrath, MacMillan, & Venkataraman
(1995), these firms can gain considerable advantages in commercializing their bio-
technology products quickly and efficiently. Much depends, however, on the spon-
sors’ willingness to share these resources and the relatedness of the CVs’ products
to the sponsors’ products. Even when the products are somewhat related, they
demand different production, marketing and distribution systems, a factor that has
led some corporations to give their CVs greater autonomy in their operations.
These observations suggest that both CVs and IVs have advantages of their own.
The implications of these advantages for product commercialization activities have
not been studied and are not well understood, a gap in the literature this study
aims to fill. Other factors might challenge the expectation that CVs will surpass
IVs in their emphasis on commercialization. For instance, some corporate sponsors
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may have elaborate control systems in place (Burgelman & Sayles, 1986); these
controls can slow new ventures’ commercialization activities. Thus, some CVs may
become slow in commercializing their products.
IVs are expected to emphasize the commercialization of new products as a
strategic priority in their manufacturing strategies more than CVs. IVs have to
quickly commercialize their products, otherwise they risk failure. The IVs’ limited
resources do not allow them to sustain significant losses for a long period of time
(Shrader & Simon, 1997). Biotechnology IVs frequently depend on the success of
their first product to support R&D for other products in their research pipeline.
After having spent significant resources over several years developing a single
product, IVs will be eager to enter commercialization immediately after FDA
approval (BIO, 1998). Consequently, most ventures will have elaborate plans in
place prior to FDA approval to speed up commercialization (Edwards, 1997). Strong
manufacturing capabilities, therefore, enhance commercialization (Wheelwright
& Clark, 1992), and the IVs’ manufacturing strategies will reflect this urgency.
Therefore:
H3: IVs will emphasize technology commercialization more than CVs.
Quality as a Manufacturing Thrust. Determining the thrust of the manufactur-
ing strategy also requires attention to quality, a factor that can affect a new venture’s
ability to build market share and gain profitability (Buzzell & Gale, 1987; Carter
et al., 1994; Minor et al., 1994). Some research, therefore, has sought to delineate
the major dimensions of quality (Hunt, 1992) and relate them to competitive success.
This study examines the overall level of emphasis placed on product quality as a
key dimension of a biotechnology venture’s manufacturing strategy (Carter et al.,
1994). If significant differences are found between CVs and IVs in emphasizing
product quality, then future research can investigate the variations between the
two venture types in particular quality dimensions.
Quality is particularly important among biotechnology companies because of
the strict standards imposed by regulatory agencies on the industry (Pisano &
Wheelwright, 1995; Voss & Allegra, 1998). The complex designs associated with
biotechnology products also make it imperative to achieve high reliability and
consistency in manufacturing operations. Minor changes in manufacturing processes
invite close scrutiny by regulatory bodies and firms have to conduct additional
clinical tests. Failure to meet or maintain high quality standards can lead to the
failure of biotechnology ventures. Therefore, the firm should use its resources to
achieve the desired levels of quality (Hayes, Wheelwright, & Clark, 1988; Minor
et al., 1994). Manufacturing capabilities can also determine a firm’s ability to meet
customer specifications, make its products easier and safer to use, and increase
product durability and reliability. It also enables the venture to maintain high quality
standards.
Even though both biotechnology IVs and CVs can benefit significantly from
emphasizing high product quality, McDougall et al., (1992) found that information
technology IVs emphasized this variable in their manufacturing strategies signifi-
cantly more than CVs. This finding is consistent with the niche strategy typically
followed by many IVs. Offering high quality products usually helps IVs differentiate
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their products from those made by their rivals. In reality, IVs have little choice but
to stress high product quality to attract customers because these firms usually
lack the financial resources or experience needed for broad marketing efforts.
Biotechnology IVs can also use their reputation for making high quality products
as a major “bargaining chip” in securing the capital needed to fund their ongoing
operations. Therefore:
H4: IVs will emphasize a higher quality in their manufacturing strate-
gies than CVs.
Low Cost/Low Price as a Manufacturing Thrust. The growth of the biotechnol-
ogy industry is explained, in part, by its capacity to offer relatively inexpensive
substitutes for existing drugs and chemicals (Burrill & Lee, 1991). Consequently,
pricing is important in examining the biotechnology ventures’ manufacturing strate-
gies. Burrill and Lee (1992) observe that: “Price competition . . . is a growing market
reality. Discounts, promotions, and pure marketing muscle are becoming critical
determinants of success” (p. 27). Biotechnology companies have to offer inexpensive
substitutes for generic drugs because insurance companies and hospitals are under
enormous pressure to lower the costs of health care. In turn, these groups have
pressured biotechnology and drug companies to lower their manufacturing costs.
Strong manufacturing capabilities can determine the success of this strategy. CVs
and IVs are expected to differ significantly in their use of low-cost, low-price
manufacturing strategies.
Biotechnology firms face serious price pressures. Though life-saving therapeutics
may command premium prices, the ongoing consolidation of the health insurance
industry creates significant pricing pressures. In spite of competitive pressures being
lower due to patent protection and FDA approval processes, CVs are expected to
emphasize low cost orientation more than IVs because of their reliance on a broader
product portfolio (Hypothesis 1) and higher levels of product innovation (Hypothe-
sis 2). As CVs have more revenue generating products than IVs with shared over-
head costs in manufacturing plants and equipment, they are less likely to charge
higher selling prices than IVs that have fewer products on the market. Thus, while
pricing strategies depend on the nature of the biotechnology products and given
that IVs may offer high quality and highly differentiated products, they are expected
to charge higher prices than CVs. This expectation does not, however, suggest a
linear relationship between price and quality. With the prevalence of innovative
manufacturing systems, biotechnology ventures can offer their diverse customers
(doctors, insurance companies, and hospitals) low price, high quality products.
Still, comparatively speaking, IVs are expected to charge higher prices for their
differentiated products more than CVs. This is especially true because of CVs’
access to their sponsors’ existing facilities and other resources that can lower their
manufacturing costs. CVs’ sponsors can also enforce tight cost controls on their
firms, a factor that can also lower the CVs’ overall costs (Burgelman & Sayles,
1986). Therefore:
H5: CVs will emphasize a lower cost orientation in their manufacturing
strategy than IVs.
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Competitive Approaches and Sources of Manufacturing. New ventures also need
to develop or acquire those manufacturing capabilities needed to transform their
chosen strategic thrusts into actual market achievements. These ventures can in-
crease their capital spending to build capabilities internally, vertically integrate, or
outsource some of their manufacturing, as discussed below.
Capital Spending. A major challenge facing biotechnology companies today is
the lack of adequate manufacturing infrastructure. This deficiency, which may result
from the ventures’ newness or lack of resources, can handicap the effective execution
of manufacturing strategies (Thayer, 1993; 1995). To overcome this deficiency, a
biotechnology venture needs to invest in developing an appropriate infrastructure
that allows it to achieve efficiency, enjoy smooth operations, quickly commercialize
its products, and achieve success. Infrastructure typically embodies a firm’s manufac-
turing facilities, technologies, and human capital. Individually and in combination,
these areas can lead to important manufacturing capabilities (Grant, 1995; Wheel-
wright & Clark, 1992). Capital spending, for example, can spur process innovations
that ensure the successful manufacturing of new biotechnology products. Process
innovations are important because of the complexity of new biotechnology products
and the high quality standards expected by regulatory agencies and customers
(Pisano & Wheelwright, 1995).
The CVs’ access to their sponsors’ resources, broad market scope, and prolific
product introductions are expected to encourage greater capital spending than IVs.
The need for capital spending becomes greater if CVs differ significantly from
their sponsors’ traditional businesses, as is happening with the CVs established by
pharmaceutical companies (Thayer, 1995). Given the inherent differences in the
production technologies and methods between these ventures and their sponsors,
heavy capital spending is necessary to build and support the CVs’ manufacturing
operations. Therefore:
H6: CVs will emphasize capital spending in their manufacturing strate-
gies more than IVs.
Vertical Integration. Biotechnology new ventures also need to consider whether
or not to vertically integrate their operations as they seek to develop their manufac-
turing capabilities (Shan & Song, 1997; Thayer, 1993). Vertical integration can
determine a new venture’s economies of scale and scope (Buzzell & Gale, 1987),
its control over the quality of its products, and the timing of its product introductions.
Despite the potential importance of vertical integration for the development of
manufacturing capabilities, it has significant drawbacks. Besides being costly and
time consuming, vertical integration can create a dysfunctional bureaucracy that
slows effective responses to the venture’s market, a factor that may explain the
reluctance of biotechnology ventures to pursue this strategy (Burrill & Lee, 1992).
Moreover, flexible manufacturing systems have increased a company’s capacity to
make a variety of products and achieve economies of scope (Galbraith & DeNoble,
1992), without the use of vertical integration. Similarly, the increased modularity
of manufacturing processes into transportable “core manufacturing competencies,”
where a firm can perform some activities internally and contract out other functions,
also reduce the venture’s need for vertical integration (Galbraith & DeNoble, 1992).
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Recent work on alliance profiles of biotechnology firms has investigated the
performance effects of horizontal or vertical linkages (Powell et al., 1996; Shan et al.,
1994). However, little is known specifically about the extent of vertical integration in
biotechnology ventures’ manufacturing strategies. Still, theory would suggest that
few IVs would pursue this option and would use substitutes for vertical integration.
IVs’ limited resources will curtail their desire to vertically integrate their operations.
Such integration may also increase the founders’ administrative responsibilities and
slow down the firm’s operations. In contrast, CVs are expected to pursue vertical
integration more aggressively than IVs. CVs’ access to their sponsors’ resources
and broad scope often encourages the pursuit of this strategy. CV sponsors may
have an incentive to vertically integrate the new venture’s activity to avoid loss of
control over the operations and reduce information leakage about its progress
toward new product development or commercialization. Therefore:
H7: CVs will emphasize manufacturing vertical integration more
than IVs.
Manufacturing Sourcing. External sources can also help in building a venture’s
manufacturing capabilities that lead to high NVP (Hayes et al., 1988; Lerner, 1997a).
External sources complement and enhance the venture’s internal sources. New
ventures, therefore, use both external and internal sources. External sources can
give biotechnology new ventures raw materials, semi-finished goods, and other
items from multiple sources, thereby overcoming these ventures’ lack of vertical
integration. External sources also quicken the ventures’ acquisition of manufactur-
ing capabilities (Lerner, 1997b; Shan & Song, 1997).
Even though both CVs and IVs make use of external sources, CVs are more
likely to emphasize external sourcing than IVs because they usually target a larger
market and offer a variety of products. Pressured to meet these needs, many CVs
may find external sourcing an attractive strategy. The established reputations of
corporate sponsors may also simplify the ventures’ access to a network of suppliers,
a factor that encourages new ventures to outsource their manufacturing and reduce
the sponsors’ financial burdens. Outsourcing can also reduce production costs.
Conversely, IVs must work hard to build a network of suppliers over several years
because they must overcome the liabilities of newness and establish trust with their
potential suppliers. Therefore:
H8: CVs will emphasize external sources more than IVs.
Manufacturing Strategy and NVP
The proposition that the content of the manufacturing strategy is conducive to
superior company performance has been supported in the literature (Vickery et
al., 1993). Yet, a review of past research (Minor et al., 1994) shows that only a few
studies have been conducted on this issue, and most evidence is derived from
samples of established companies (Vickery et al., 1993), which raises a question
about their generalizability to new ventures. This study aims to fill this gap in the
literature.
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The study advances three points about the potential relationship between a
biotechnology venture’s manufacturing strategy and its performance. First, this
strategy is expected to significantly influence the NVP by helping to focus the
venture’s investment in building or acquiring those manufacturing capabilities that
enable it to meet customer needs. Prior research (e.g., Stuart & Abetti, 1987)
suggests that new ventures that offer innovative products enjoy high NVP. Further,
NVP is improved by having high quality products (Block & MacMillan, 1993).
Sourcing can also reduce manufacturing costs, enhance the acquisition of capabili-
ties, and improve NVP.
Second, manufacturing strategy variables can influence new ventures’ innovative
outputs, especially patenting activities. Patents represent an important milestone
in biotechnology new ventures’ progress toward creating and commercializing new
products. They also enhance the ventures’ reputation for innovation and technologi-
cal leadership, and represent an important asset that is highly valued by the market,
investors and venture capitalists. Given these benefits, biotechnology firms have
devoted considerable resources to obtaining patents. This study extends the litera-
ture by exploring the potential associations between a new venture’s manufacturing
strategy variables and its patents, aiming to establish if the content of manufacturing
strategy variables contribute to the ventures’ innovative outputs.
Third, not all manufacturing choices are conducive to superior NVP. This is
especially true in the early years of the venture’s life cycle, where a firm must
invest heavily in developing or acquiring manufacturing capabilities. While these
investments are necessary, they may not improve the performance of biotechnology
new ventures. Given that Hypotheses 1 through 8 posit that CVs and IVs will pursue
different manufacturing strategy variables, it follows logically that manufacturing
strategy variables differentially impact the performance of CVs and IVs. That is,
each venture type is expected to bundle up its chosen manufacturing strategy
variables differently to achieve high performance. This suggests that those manufac-
turing variables predicted to form the content of CVs’ manufacturing strategies are
expected to significantly influence their performance. The same logic applies to the
variables predicted to constitute the IVs’ manufacturing strategies. Therefore:
H9: The association between manufacturing strategy variables with
financial and innovative performance will vary significantly be-
tween CVs and IVs.
METHOD
Sample and Data
Data from new U.S.-based biotechnology ventures were used to test the study’s
hypotheses. Although several researchers have examined this important industry
(e.g., Hamilton & Singh, 1992; Walker, Kogut, & Shan, 1997; Shan & Song, 1997),
they have offered little documentation of the content of the ventures’ manufacturing
strategies or their implications for NVP. As noted previously, the biotechnology
industry was chosen for study because of its importance as a high technology frontier
(Carey et al., 1997) that has stimulated the creation of hundreds of new ventures. The
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number of U.S. biotechnology companies has grown from 470 (Office of Technology
Assessment, 1988) to 1287 in 1997 (BIO, 1998). The industry raised a total of $7.8
billion capital in 1997 for new ventures and strengthened existing research programs
(BIO, 1998). With the potential for high profits coupled with high risk and intense
competition, the industry has pressured new ventures to build their core competen-
cies to survive and succeed.
The newness of the biotechnology industry itself, raises a question as to the
manufacturing capabilities required for achieving superior performance. The indus-
try represents a paradigm shift, which challenges the efficacy of traditional manufac-
turing systems and practices. Biotechnology companies have to struggle to find
which manufacturing choices work and which ones fail. Companies often have
to do this while under significant pressures to be more efficient. For example,
biotechnology firms including Chiron have incurred the wrath of Wall Street analysts
because of ineffective manufacturing practices (Piercey, 1996). Analysts believe
that biotechnology companies should strive to reduce their costs of goods sold in
order to maximize profit margins and generate cash to sustain on-going R&D
expenses.
Data were collected by a mail survey that allowed simultaneous access to many
new ventures. This was desirable because public sources did not contain detailed
information about some of the key manufacturing strategy variables explored in
this study (e.g., cost orientation). Also, most IVs did not publish annual reports, and
data on CVs were subsumed within the sponsors’ operations. As reported below,
wherever possible, secondary data were also collected to verify the survey data.
The development of the survey went through several iterations. The original
questionnaire was revised based upon feedback from 17 venture managers (not
included in the main study) and a follow-up review by three biotechnology managers.
The final survey targeted the ventures’ chief executives officers (CEOs) or highest
ranking managers, considered the most knowledgeable individuals about the new
ventures’ operations (Kazanjian & Drazin, 1990).
Company names and addresses were gathered from New Developments in Bio-
technology (Office of Technology Assessment, 1988), Bioscan (1989), North Caro-
lina Companies in Biotechnology (several years), and the Philadelphia Inquirer’s
(1991), and three leading newspapers (Los Angeles Times, New York Times, and
Washington Post), all for the 1989-91 period. Combined, these sources produced
893 names.
To be included in this study, a venture had to meet three criteria. First, to be
considered a “new venture,” the firm had to be in existence for eight years or less,
as done in prior research (Biggadike, 1976; McDougall et al., 1992). Second, the
firm had to be headquartered in the U.S., thereby limiting the geographic scope of
the research. Third, the venture had to be active in one or more of the major areas
that constituted the domain of the biotechnology industry: human diagnostics,
pharmaceutic/therapeutic, specialty chemicals, plant agricultural, animal agricul-
ture, food processing, waste management, and equipment/appliances (Burrill &
Lee, 1992; Office of Technology Assessment, 1988). The third criterion ensured the
inclusion of companies that actually engaged in the development, production and
marketing of biotechnology products while excluding venture capitalists and other
companies that offered consulting and other services to the industry. Using the
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above three criteria, 443 ventures were identified and surveyed. However, 54 ques-
tionnaires were undeliverable because the companies moved or ceased to exist.
Two mailings conducted one month apart yielded 112 completed responses; a re-
sponse rate of about 29%.
Responding ventures averaged 4.9 (sd 5 2.4) years in age and employed 71 (sd 5
57) people. These ventures were located in different parts of the U.S.: 17% in San
Francisco, 15% in New York, 15% in Washington, D.C., 10% in Boston, 7% in
Los Angeles, 12% in San Diego, and the remaining 23% operated in 29 other
regions or states. Finally, 68 (64.15%) were IVs and 38 (36.85%) were CVs.
Three steps were followed to determine the absence of response bias. First,
responding companies were compared to non-responding companies on: age (t 5
.94, p , .41), employees (t 5 1.07, p , .23), and sales growth (t 5 .83, p , .44).
Second, the x2 test compared responding and non-responding ventures by ownership
(CVs vs. IVs). This test was insignificant (p 5 .29), indicating that there was no
significant relationship between participation in the study and ownership type (CVs
vs. IVs). Finally, using the t-tests, respondents to the first and second mailings were
not significantly different in age (t 5 .69, p , .46), employees (t 5 .73, p , .38),
and sales growth (t 5 .79, p , .31). Although these analyses indicated that the sample
represented its target population, caution is necessary in making generalizations to
established companies or ventures located outside the U.S.
Other factors indicated the absence of response bias. For example, most of the
surveys were completed with only minimum levels of missing data (surveys with
excessive missing data were excluded in calculating the response rate). Also, many
respondents provided detailed comments about their company’s operations. Fur-
ther, 70% of the respondents requested summaries of the results, showing their
interest in the study. To establish the reliability of the data, the questionnaire was
sent to a second senior manager in each responding venture (n 5 112). Forty-seven
of these managers returned completed responses, which were then matched with
replies from the main survey. Correlations indicated significant agreement on each
of the manufacturing strategy variables (p , .01 or better). Previous research has
shown strong convergent validity between perceptual and archival measures of
strategic choices (Carter et al., 1994, p. 27).
Measures
The data used in this paper are a part of a larger study on the dynamics of
competition in the U.S. biotechnology industry. Measures of the venture’s origin,
manufacturing strategy, NVP, and control variables were developed.
Venture Origin. Ventures created and run by individual entrepreneurs were
classified as “IVs” (n 5 68). Ventures owned by established firms were classified
as “CVs” (n 5 38). This classification was consistent with prior research (e.g.,
McDougall et al., 1992; Shrader & Simon, 1997). However, six firms were excluded
from analysis because of changes in their ownership between the time of their
establishment and data collection. Four IVs were later acquired by corporations.
At the time of the data analysis, two of these ventures were being “spun off” by
their corporate sponsors and their future was uncertain. Two CVs were redesignated
“joint ventures” by their sponsors. Given the small number of joint ventures and
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other non-classifiable firms in the sample, the six firms were excluded from further
consideration. Thus, the analyses reported in this paper are based on 106 of the
112 responding firms.
Manufacturing Strategy. The Appendix presents the measures of the new ven-
tures’ manufacturing strategy variables, each of which was measured by a multi-
item index.1 As noted in the Appendix, significant associations were found between
archival and survey-based measures for a subset of the responding companies,
further supporting the validity of the survey-based measures. Still, caution is neces-
sary because lack of secondary data made it impossible to validate all of the study’s
measures.
New Venture Performance (NVP). Biggadike (1976) observed a lack of agree-
ment on the domain and measurement of NVP. Yet, the complexity of NVP makes
the use of multiple indicators a must (Brush & VanderWerf, 1992; Chandler &
Hanks, 1993). Using different measures can more comprehensively gauge NVP,
thereby giving a more accurate assessment of a venture’s performance. Conse-
quently, this study used three NVP measures, covering a 3-year period each.
Growth in sales (measured as a percentage) has been widely used in past research
(Biggadike, 1976; Feeser & Willard, 1990). Brush and VanderWerf (1992) also
suggest that growth in sales is among the most commonly used criteria and is
considered superior to many other NVP measures (Chandler & Hanks, 1993).
Secondary and survey data were then correlated for a subset of the sampled ventures
(r 5 .71, n 5 23), further supporting the validity of the survey measure.
Market share growth, the second objective NVP measure, has also been used in
past empirical research (e.g., McDougall et al., 1992) because it reflects a venture’s
ability to build market share, which is important for profitability (Buzzell & Gale,
1987). Given the vague boundaries of the emerging biotechnology industry (Grant,
1995), market share data may present an inaccurate measure of NVP. Further, the
fact that companies themselves defined market share growth raises the possibility
that these firms defined this variable differently, adding noise to the data.
Satisfaction with performance was also measured using a multi-item index (refer
Appendix). Executives rated their satisfaction with each item, weighted by that
item’s importance. The performance index is derived from past research (e.g.,
Covin & Slevin, 1990; Stuart & Abetti, 1987) and supplements the information
gained from the other two objective NVP criteria. Inter-rater agreement on the
index was .67 (n 5 47, p , .001) and Cronbach-a was .85. Three additional factors
indicated the validity of the NVP index. First, when factor analysis was used, it
produced one significant factor, which supported convergent validity of the index.
Second, the content validity of the index (i.e., the extent to which the measure
adequately reflects the theoretic domain of NVP) was supported by the literature.
Third, the correlations of the index with objective performance measures were
significant (all at p , .001): growth in sales (r 5 .64) and growth in market share
(r 5 .59), supporting the criterion validity of the index.
New Venture Innovative Output. To gauge the venture’s success in patenting,
a three-item scale was used. As reported in the Appendix, this measure correlated
significantly with the number of applications for patents (n 5 41; p , .01) and the
number of patents obtained by 71 of the responding firms (p , .001).
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Control Variables. Three variables were used as statistical controls: the ven-
ture’s age, size, and market scope. Research shows that ventures’ age and size may
influence their performance (Powell et al., 1996; Shan et al., 1994). The ventures’
participation in certain markets varies also by their age and size (Burrill & Lee,
1991). Consequently, both the ventures’ age and size were included as controls in
the analysis of NVP. Age was measured by the number of years a new venture has
been in existence. Size was measured by the number of the venture’s full-time
employees. The market scope of the venture was used as a third control variable
because it might have influenced the choices of many of the venture’s manufacturing
strategies (Hofer & Sandberg, 1987), such as the number of new products. Market
scope was measured by the number of segments pursued by a venture.
ANALYSIS
Hypotheses 1 through 8 were tested using the t-test and discriminant analysis. T-tests
initially determined the variations between the CVs and IVs in their manufacturing
strategy variables. T-tests were then followed by a two-group discriminant analysis
to establish if and where the CVs and IVs differed in their overall manufacturing
strategies. After examining the classification matrix, significant discriminant loadings
helped to identify manufacturing strategy variables that significantly separated CVs
from IVs.
Hypothesis 9 was tested using multiple regression analysis, where the three NVP
measures were treated as the “dependent” variables and the manufacturing strategy
measures were entered as “predictors.” The six regression analyses performed to
test H9, a new venture’s age, size and market scope were first entered as statistical
control variables, followed by the manufacturing strategy variables.
To examine the associations between the content of manufacturing strategy
variables and patents, regression analysis was used. Initially, two separate regres-
sions (one for the IVs and the other for the CVs) were attempted, following the
procedure just described for financial performance. The dependent variable in both
analyses was the company’s self-reported “emphasis on patenting.”
RESULTS
Testing H1 Through H8: The Content of Manufacturing Strategies
Table 2 displays the mean scores for CVs and IVs. The t-tests revealed that CVs
were significantly younger and larger than IVs (both at p , .05). CVs, however,
pursued more broadly defined markets than IVs (p , .01). The CVs emphasized
the following variables significantly more than IVs: product breadth, low cost, capital
spending, vertical integration, and external sourcing. IVs exceeded CVs in product
innovation and commercialization. The two venture types did not vary significantly
in quality.
Repeated t-tests ignored the interrelationships among the venture’s manufactur-
ing strategy variables (Hair et al., 1992) and, therefore, a discriminant analysis was
performed. Before conducting this analysis, all manufacturing strategy variables
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TABLE 2
T-tests of Manufacturing Strategies and Performance:
Independent vs. Corporate Ventures
Origin
Scale Independent Corporate
Variables # Items a (IV) (CV) t-value
Manufacturing Strategy
(a) manufacturing scope:
Product Line Breadth 3 .72 2.61 3.68 22.01*
(b) manufacturing thrust:
Quality 3 .71 3.41 2.98 1.02
Product innovation 3 .74 3.21 2.09 2.97**
Commercialization 2 .67 3.41 2.31 2.11*
Low Cost 3 .67 1.90 3.44 23.02**
(c) manufacturing sourcing:
Capital Spending (internal) 3 .73 2.21 3.46 22.11*
Vertical Integration 3 .73 1.63 3.51 22.16**
External Sourcing 4 .70 2.25 3.66 21.99*
General Characteristics
Age (years) 5.82 3.31 2.09*
Size (employees) 63.12 88.09 22.17*
Market Scope 1.11 3.53 23.31**
Internal consistency for the 2-item scale was measured using simple r.
* p , .05.
** p , .01.
*** p , .001.
were standardized (mean 5 0; sd 5 1) because the measures had different scales.
CVs and IVs were then coded 0 and 1, respectively; therefore, a positive sign
showed that IVs significantly surpassed CVs on a given variable and vice versa. A
venture’s age, size and market scope were also included in the discriminant analysis.
Following Hair et al. (1992), discriminant loadings with an absolute value of .30
or above were significant. Loadings, which showed the contribution of a variable
to a multivariate set, were more stable than simple coefficients and were therefore
emphasized in interpreting the data in Table 2. The analysis yielded one significant
function (canonical correlation 5 .81, Wilks’ l 5 .21) that correctly classified 83.3%
of the ventures. This ratio exceeded the value of Press’ Q of 43.01 (p , .001),
indicating that the discriminant function successfully separated the CVs from the
IVs. The classification matrix appears in Table 3.
The results from discriminant analysis (Table 4) were consistent with the t-test
results presented earlier, with the exception of vertical integration. Nine of the
eleven variables included in the analysis were significant (with absolute loadings
of .30 or higher). Six of the nine significant variables were manufacturing strategy-
related, of which the product line breadth contributed the most to the discriminant
function (i.e., it had the largest loading). It was followed by (in a descending order):
commercialization, product innovation, capital spending, low cost, and external
sourcing. Emphasis on quality and vertical integration were not significant. Though
not statistically significant in the discriminant analysis, t-test results (Table 2) show
that CVs stressed vertical integration in manufacturing strategies more than IVs (t-
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TABLE 3
Discriminant Analysis of Technology Strategy Variables:
Independent vs. Corporate Ventures
Expected Coefficient Loadings
Variables Signa (weights) (structure correlation)
Manufacturing Strategy
(a) manufacturing scope:
Product Line Breadth 2 2.76 2.74
(b) manufacturing thrust:
Quality 1 .37 .21
Product innovation 2 2.62 2.59
Commercialization 1 .66 .66
Low Cost-Low Price 2 2.55 2.43
(c) sources of mnfg. capabilities:
Capital Spending 2 2.59 2.57
Vertical integration 2 2.26 2.17
External Sourcing 2 2.32 2.43
General Characteristics
Ageb 1 .46 .33
Sizeb 2 2.31 2.35
Market Scopeb 2 2.42 2.36
a Independent ventures 5 1 (n 5 68) and corporate ventures 5 0 (n 5 38).
b Control variables.
value 5 22.16, p , .01). Finally, CVs were significantly larger and had a significantly
broader market scope than IVs. However, the IVs were significantly older than CVs.
Testing H9: The Correlates of IVs’ versus CVs’ Performance
Biotechnology IVs and CVs reported 19.79% and 10.02% growth in sales, respec-
tively (t 5 4.11, p , .001). IVs and CVs also had scores of 3.45 and 2.69, respectively,
on the NVP index (t 5 2.27, p , .05). However, with scores of 3.01% and 3.16%,
respectively, IVs and CVs did not differ significantly in market share growth.
To test H9, three separate regression analyses were performed for the IVs and
CVs, for a total of six runs. In these analyses, market share growth, sales growth,
and an overall performance index were treated as the “dependent” variables. In
each analysis, the study’s control variables (age, size and market scope) were first
entered, followed by the manufacturing strategy variables, as reported in Table 5.
TABLE 4
Discriminant Analysis: Cross-Classification Matrix
Venture Type
Venture Type Independent Corporate
Independent 54 7
Corporate 14 31
% Correctly Classified 5 83.3
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The analyses for the IVs were significant, explaining between 17 and 27% of
variance in NVP. Quality and commercialization were positively and significantly
associated with the IVs’ three performance measures. Product innovation was posi-
tively associated with both sales growth and market share growth. Vertical integra-
tion and external sourcing, however, were negatively and significantly associated
with the three measures of the IVs’ performance. Further, the IVs’ product line
breadth, low cost, capital spending, age, size, and market scope were not significant
in the three regressions.
The regressions for the CVs were also significant, explaining between 19% and
23% of variance in the performance measures. Product line breadth was positively
associated with all three NVP measures. Low cost manufacturing orientation and
external sourcing were positively associated with both market share growth and
the performance index. Commercialization and high quality were positively associ-
ated with the overall performance index. However, both capital spending and
vertical integration were negatively associated with the CVs’ three performance
measures, while product innovation was not significant in any of three regression
equations. Finally, as the data in Table 5 show, the CVs’ age and size were signifi-
cantly and positively associated with the three NVP measures, whereas the CVs’
market scope was significantly and positively associated only with sales growth.
The Results for Patents
The regression results for patenting appear in Table 6, where the patenting index
was regressed on manufacturing strategy variables after introducing the statistical
control variables. Separate analyses were performed for CVs and IVs. As Table 6
shows, the regressions explained 11% and 7% of the variance in the patenting
index. The regression was significant for IVs but insignificant for CVs. Also, among
IVs, product line breadth was positively and significantly associated with patenting,
but sourcing was negatively associated with this variable. IVs’ age (one of the
control variables) was also positively associated with the patenting index. Though
the equation for CVs was not significant, sourcing and company age had positive
and significant associations with patenting.2
DISCUSSION
The results contribute to our understanding of the role of manufacturing strategy
in determining the success of young, high technology firms. Despite the progress
made in studying the overall competitive strategies of new ventures (Carter et al.,
1994), little attention has been given to the role of manufacturing in determining
the success and failure of these young companies (Galbraith & DeNoble, 1992).
The results clarify some of the differences between the profiles of the CVs and IVs
in the biotechnology industry. Even though researchers have looked into particular
strategic choices (e.g., alliances) that determine biotechnology companies’ perfor-
mance (Powell et al., 1996; Liebeskind et al., 1996), they have not analyzed the
differences in manufacturing strategies within an emerging high technology industry.
Using data from biotechnology new ventures, this study extends the literature by
showing that: CVs and IVs emphasize significantly different manufacturing strategy
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TABLE 6
Manufacturing Strategy of Independent vs. Corporate
Ventures’ Patenting: Regression Results
Emphasis on Patenting Index Actual Patent
IVs CVs Count
Intercept 1.26 2.57 1.04
Age .19* .24* .28*
Size .13 .11 .23*
Market scope .07 .02 .10
Venture origin (IVs 5 1) .37**
Manufacturing Scope
Line Breadth .23* .12 .09
Manufacturing Thrust
Quality .04 .03 .01
Product Innovation .15 .07 .03
Commercialization .09 .14 .15
Low Cost-Low Price .07 2.03 2.07
Manufacturing Sourcing
Capital Spending 2.12 .04 2.05
Vertical Integration .13 2.11 2.01
Sourcing 2.29* .31* .21*
R2 5 .11 .07 .11
F 5 3.11* 1.08 2.91*
* p , .05.
** p , .01.
*** p , .001.
variables; manufacturing strategy variables significantly influence NVP; and signifi-
cantly influence the performance of CVs and IVs. This section develops these three
points.
The Content of Biotechnology CVs’ versus IVs’ Manufacturing Strategies
The results supported six of the study’s eight hypotheses on the content of new
ventures’ manufacturing strategies. As predicted, CVs had significantly higher scores
than IVs in: manufacturing product line breadth (H1), product innovation (H2),
low cost manufacturing orientation (H5), capital spending (H6), and external sourc-
ing (H8). Conversely, but still consistent with predictions, IVs emphasized commer-
cialization (H3) significantly more than CVs.
Even though the above findings are consistent with expectations, the results on
product line breadth and the low cost manufacturing orientation contradict the
results reported by other researchers. For example, the results on product line
breadth are in conflict with those reported by Shrader and Simon (1997), who found
no significant differences between the CVs’ and IVs’ emphasis on market breadth.
These different findings might reflect differences in the samples and the measures
used.
As noted earlier, viewed in the context of the biotechnology industry, a broad
product line may not be desirable. A broad product line would require significant
additional R&D expenditures to maintain and support these products. Each new
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drug requires an investment of about $200–$350 million over a time frame of seven
to twelve years (BIO, 1998). The capital investment needed to support a broad
product line is more likely to come from a stable CV (with established pharmaceuti-
cal partners) than from an IV. For example, Amgen Inc. (the largest independent
biotechnology company in the U.S.) founded in 1981 launched its first product
(Epogen) in 1989, its second (Neupogen) in 1996, and its third (Infergen) in 1997.
Amgen conforms to the general trend that biotechnology ventures support new
product additions by generating cash from a single blockbuster product (Edwards,
1998). Biotechnology companies appear to broaden their portfolio only after the
success of their narrow product strategy.
A strategy of a single-product focus can be risky. The failure and eventual
takeover of Cetus Inc., for example, has been blamed on a futile focus on interleukins
when in 1990 the FDA refused approval of its single product prototype (Liebeskind
et al., 1996). Overall, though propositions of ‘narrow’ versus ‘broad’ product portfo-
lios may have intellectual appeal, many biotechnology new ventures are constrained
by the resources available to develop a broad product portfolio. Obviously, market
and product line breadth are not the same thing; a venture can compete in a broad
market by offering a wide variety of applications with the same product line (Grant,
1995). Future studies, therefore, are necessary to clarify the extent of the differences,
if any, between the CVs and IVs in the breadth of their markets and product lines.
The fact that CVs have a significantly higher score on the low cost manufacturing
orientation (H6) also contradicts some previous results (e.g., Shrader & Simon,
1997). In the current study, CVs have a significantly higher score than IVs on low
cost manufacturing, possibly because the CVs’ sponsors (mostly pharmaceutical
and drug companies) are also under pressure to reduce costs. This pressure might
have filtered down to the CVs, highlighting the importance of reducing manufactur-
ing costs as a strategic priority. CVs might have followed this strategy to convince
their sponsors of their value-added. Pharmaceutical and drug companies have cre-
ated or acquired CVs as a means of developing and marketing drugs inexpensively
(Burrill & Lee, 1992). Thus, both the parent corporations and their CVs have an
incentive to lower the cost of manufacturing activities.
Another explanation to consider is the IVs’ and CVs’ financing practices. Nega-
tive earnings are generally not well tolerated by Wall Street investors. In particular,
reactions to lower than expected earnings reported by established pharmaceutical
corporations that typically tend to be large-capitalization stocks are harsher than
reactions to independent ventures that are small. Pharmaceutical firms have a large
market capitalization and are traded for high price-earnings multiples. Therefore,
a relatively small change in earnings would be reflected as a large drop in stock
price. Because these corporations have several products on the market, investors
follow earnings’ news closely. Hence, these firms attempt to streamline production
costs to improve profit margins (Piercey, 1996). On the other hand, stock valuation
for independent ventures is based largely on future product potential than on
existing earnings, which reduces the need for a low cost orientation. For example,
Merck Inc., a large pharmaceutical firm with a market capitalization of nearly $150
billion can be more volatile in comparison to a $83 billion capitalization of all
independent biotechnology ventures in the U.S. (BIO, 1998). Emphasis on cost
savings and improved profit margins, therefore, is stronger in pharmaceutical firms
and CVs.
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One area where CVs and IVs do not differ significantly in their manufacturing
strategies (Tables 1 & 2) is the emphasis on quality (H4). The results on this
variable, which are counter to expectations, deserve comment. Specifically, the
finding that IVs do not have a significantly higher quality score than CVs suggests
that both venture types have understood the strategic importance of quality for
competitive success and have used this variable in their manufacturing operations.
Still, the results contradict McDougall and colleagues (1992) who found that infor-
mation technology IVs significantly exceeded their CV counterparts in emphasizing
quality. Although the differences in the two studies’ findings may stem from the
samples and measures used, the present results may be industry-specific because
the stringent FDA approval process may define biotechnology product standards.
High quality is expected from all new biotechnology ventures because the risk of
product failure because of inadequate quality does not only cause product failure
but also threatens firm survival. Thus, CVs and IVs must be high quality producers.
Future research using data from other industries, therefore, can help to determine
if significant differences exist in the relative emphasis CVs and IVs place on quality.
A clearer picture of these differences might emerge, moreover, from using a multi-
dimensional measure of quality and relating these dimensions to NVP.
Next, the t-test results suggest that CVs and IVs differ significantly in their
emphasis on manufacturing vertical integration. These results might be inconclusive
because the discriminant analyses for vertical integration were not significant, a
finding that is consistent with Burrill and Lee (1992) who observed that vertical
integration is not a high priority in the biotechnology industry. Both CVs and
IVs might have already found alternative ways (e.g., outsourcing) to acquire their
capabilities without vertically integrating their manufacturing (Carey et al., 1997;
Lerner, 1997a,b). Given the cross-sectional nature of the current database, one
cannot conclusively identify the reasons for or against the ventures’ vertical integra-
tion. By tracking their strategic choices over time significant differences between
the CVs and IVs in backward and forward manufacturing integration can be better
understood.
Overall, the results show that biotechnology CVs and IVs pursue different manu-
facturing strategies, reflecting different ways to reach customers and achieve high
performance. Not all of the manufacturing choices made by biotechnology CVs
and IVs are associated with high NVP. Consequently, the study sought to identify
those manufacturing variables that are significantly associated with NVP, as dis-
cussed next.
Manufacturing Strategies and NVP (Hypothesis 9)
The study also examined the associations between the manufacturing strategy
variables and measures of the financial and innovative performance of new ventures.
This section reviews the study’s findings in this regard.
New Venture Performance. The results support H9 by revealing that the perfor-
mance of biotechnology CVs and IVs usually benefit from different sets of manufac-
turing strategy variables. Quality and commercialization are positively associated
with the IVs’ three NVP measures. Product innovation is also positively associated
with growth in sales and market share. Conversely, the performance of the IVs is
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negatively associated with external sourcing and vertical integration. However,
Table 5 reveals that the CVs’ performance is enhanced by an emphasis on having
a broad product line. CVs’ share growth and overall performance index are also
positively associated with external sourcing and a low cost orientation.
When the results for the CVs and IVs are compared, six trends are noted in the
data. First, whereas a broad product line is conducive to high performance among
CVs, the same variable is negatively (but insignificantly) associated with the three
measures of CVs’ performance. IVs, therefore, do not appear to gain a performance
advantage from a broad product line, which supports H2. Resource constraints
often compel IVs to pursue focused manufacturing operations.
Second, IVs also benefit from emphasizing quality more than CVs (Table 5),
even though the two venture types do not vary significantly in their quality scores
(Table 3). Thus, while CVs and IVs may stress quality about equally, they may do
so differently. Differences in implementing quality, therefore, may explain the
variations noted in the association of quality with NVP.
Third, commercialization and a strong focus on product innovation are more
important for the IVs’ than the CVs’ successful performance. One reason is the
IVs’ limited resources and narrow market (and product) focus, which pressure these
companies to excel through innovation and rapid commercialization.
Fourth, the positive and significant signs found between manufacturing external
sourcing and the CVs’ market share growth and the overall NVP index is contrasted
with the negative signs found with the IVs’ three performance measures. Sometimes,
external sourcing negatively impacts the IVs’ performance because of the rising
costs of coordinating the inputs obtained from different suppliers. IVs have to
integrate externally acquired capabilities with their internal skills, which can depress
short-term performance (Zahra & Das, 1993).
Fifth, the results indicate that capital spending has negative signs with the three
NVP measures of both venture types, but it is significant only among CVs. These
negative signs are consistent with Marshall and Buzzell (1990) who reported a
significant negative association between capital spending and performance. Thus,
while capital spending is important for having an up-to-date manufacturing infra-
structure, it may be a necessary–but insufficient–condition to gain superior short-
term NVP because the payoff from capital spending may take years to materialize.
Further, the contribution of capital spending to NVP may be indirect by influencing
those manufacturing capabilities that enable the venture to exploit growth opportu-
nities in the industry. Longitudinal analyses are necessary to establish these long-
term benefits from capital spending among new ventures.
Sixth, vertical integration is also negatively associated with the performance of
both CVs and IVs, probably because the heavy costs associated with this option
can reduce NVP (Buzzell & Gale, 1987). Vertical integration can also slow down
a new venture’s operations and weaken its ability to achieve profitability. The CVs
and IVs, therefore, should weigh this short-term negative effect against the long-
term gains they may derive from this option; it may take years for a new venture
to gain the benefits of vertical integration.
Virtually all manufacturing sourcing variables have negative coefficients in the
regression equations (Table 5). These results may be sample-specific. Still, manufac-
turing sourcing variables may be less important than other factors (e.g., marketing)
because of recent growth in contract research organizations (CROs) that perform
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batch processing, prototype development, or initial testing of products. CROs,
present in a research park or a proximate region, form clusters of high technology
firms that allow CVs and IVs to outsource more of their non-core manufacturing
activities than previously possible (Thuermer, 1997).
To summarize, the results show that the overlap between those manufacturing
strategy variables that lead to high NVP among CVs and IVs is limited. IVs and
CVs benefit from using different manufacturing strategies. This study does not
identify how new ventures implement these strategies and future research should
closely examine this issue.
New Venture Innovative Outputs (Patenting). The results also show that manu-
facturing strategy variables have a modest impact on a venture’s self reported
emphasis on patenting, and that IVs benefit more than CVs from the contributions
manufacturing strategy variables make in this regard. Perhaps, as widely believed
in the literature, the IVs’ owners have to work hard at making every thing count
toward achieving superior financial performance. IVs’ owners prior R&D experi-
ence may also help in transforming their operations into a source of innovation
and patenting. If this were true, then these owners would be more attentive to
finding ways where they can cultivate the fruits of their manufacturing investments
by gaining more patents. Further, as IVs gain experience, they focus more on
patenting, as indicated by the positive correlations noted between IVs’ age and
patenting (Table 6). Still, the results might also reflect the long discovery cycle that
characterizes biotechnology R&D activities where several years elapse between
discovery and clinical trials.
Another variable of interest in terms of patenting is the firms’ use of external
sources. Sourcing is positively associated with emphasis on patenting probably
because external sourcing can expose the firm to different sources of innovation,
which can enhance patenting. The results, however, show that the associations
between sourcing and patenting vary between CVs and IVs; sourcing has a negative
effect among the IVs but has a positive effect on patenting among CVs. It is possible
that CVs and IVs use different sourcing strategies, which would lead to variations
in the effect of sourcing on patenting. Researchers need to corroborate this finding
and identify the sources of the variations in the effect of external sourcing on
patenting.
A final variable of interest relative to patenting is product line breadth, which
was positively and significantly associated with patenting among IVs. The breadth
of the IVs’ product application can stimulate patenting. IVs’ owners are also pres-
sured to protect their discoveries by adopting a strategy of patenting to capitalize
on the applications they may develop in their operations. Also, patent royalties
may generate the funds needed for future R&D. CVs may not feel the same types
of pressures because of their access to their sponsors’ resources.
In summary, the results suggest that the content of manufacturing strategy vari-
ables have a modest effect on new ventures’ emphasis on patenting or their actual
number of patents. Where there is a significant effect, IVs appear to benefit more
than CVs in patenting from the contributions of their manufacturing strategy vari-
ables. The next section of the paper will highlight the implications of the results on
performance and content of new ventures’ manufacturing strategies for managerial
action and future research.
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Limitations and Future Research Directions
Besides the issues outlined above, the results indicate a need for more empirical
research to document changes in the priorities new ventures place on manufacturing
strategy variables over time. As biotechnology companies grow, the strategic issues
they face will undoubtedly change (Grant, 1995), requiring major changes in these
ventures’ manufacturing priorities. Theory building efforts can benefit from incorpo-
rating these evolutionary changes in new ventures’ competitive priorities and deter-
mine any corresponding changes in their manufacturing strategies (Hamilton et al.,
1990; Minor et al., 1994).
Replications with data from other industries are also necessary to validate our
findings and establish their generalizability. One drawback of this study is its exclu-
sive focus on the biotech industry. Management literature points to the importance
of industry structure in determining a company’s strategic choices. Therefore, it
would not be surprising to find industry-related differences between IVs and CVs
in their manufacturing strategies. For instance, in our study we found no difference
between IV and CV emphasis on quality. Future research can extend our findings
by including data drawn from multiple industries, thereby allowing scholars to
generalize their results to a larger population. As noted earlier, our results may
also reflect the present stage of the biotechnology industry’s life cycle or the stage
of commercialization of its products and technologies. Longitudinal research designs
are necessary to document the changes in new ventures’ manufacturing strategies
over time. These analyses can also overcome our study’s cross-sectional designs
that preclude making causal inferences about the relationship between a venture’s
manufacturing strategy and NVP. Longitudinal analyses are desirable also to under-
stand the effect of subsequent changes in the ventures’ manufacturing strategies
on any changes that may occur in NVP. Such longitudinal studies can also overcome
survivor bias, which is one of the limitations of this study. Finally, the complexity
of the biotechnology industry also suggests that a larger sample might better capture
new ventures’ strategies.
Future studies should also examine the patterns of ownership in the biotechnol-
ogy industry and how they may affect manufacturing strategy choices. More and
more new ventures are entering into strategic manufacturing alliances. Established
companies are also active in securing partial equity positions in new ventures
(Burrill & Lee, 1992). These and similar changes in the ventures’ ownership patterns
can affect their manufacturing strategy choices, especially external sourcing and
vertical integration. Future research should determine the effect of the content of
CVs’ and IVs’ manufacturing strategies on the sources of biotechnology firms’
competitive advantages. These sources might include the ventures’ ability to achieve
speedy market commercialization, develop a reputation for market responsiveness,
build a reputation for process and product innovation, and obtain patents that
are highly valued as significant technological developments. By clarifying how the
content of CVs’ and IVs’ manufacturing strategies may affect these variables, re-
searchers can also improve our understanding of the contributions of manufacturing
to the survival and success of high technology new ventures.
A related issue that deserves attention in future research is the potential differ-
ences that might exist in the CVs and IVs’ goals, structures and resources, and how
these variables influence these ventures’ strategic choices, including manufacturing
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strategies. As noted earlier, wide variations exist in how IVs and CVs are organized,
financed and managed. This study and previous research have not captured these
differences and how they influence a firm’s manufacturing strategy. Researchers
can enrich the literature by exploring these relationships.
This study contributes to theory testing and building in several ways. Using the
resource-based theory, the study offers a test of some potential of variations among
independent and corporate-owned biotechnology new ventures. Little is currently
known about the major sources of differences between these different types of
firms and how these differences may affect their strategic choices and, ultimately,
performance. Also, the study provides some insights into the importance of manufac-
turing strategy variables for NVP in a young industry. These results support the
strategic choice approach which posits that those companies that pursue effective
strategies will gain higher performance than those firms that fail use such strategies.
The results also add to our knowledge of the differences between CVs and IVs in
manufacturing strategies. This information can be useful for building and revising
theories about the sources of superior performance in the biotechnology industry.
Hamilton and Singh (1992) highlight the need to develop theories of organizational
evolution in technology-based industries such as biotechnology. As knowledge of
the types and sources of differences that exist among CVs and IVs accumulates,
better theories of determinants of NVP can also be developed.
High technology ventures contribute greatly to the growth of the U.S. economy.
Understandably, researchers have devoted considerable attention to examining the
strategies that determine the success or failure of these ventures. The current
results extend the literature by showing that manufacturing strategy can enrich new
ventures’ performance, and that independent and corporate-sponsored ventures
follow different manufacturing strategies in pursuit of superior performance.
NOTES
1. The correlations between the two sets of managerial responses to these measures
averaged .62 (p , .001) consistent with the literature (McDougall et al., 1994).
2. We also regressed the number of actual patients obtained by 71 of the firms in the
sample. Using dummy regression (IVs 5 1 and CVs 5 0), the analysis was significant and
had an adjusted R2 of .11 (p , .01). The following variables were significantly associated
with a venture’s number of patents: company age, company size, IV origin, and sourcing.
Of the significant variables, sourcing was the only manufacturing strategy-related.
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APPENDIX
This Appendix presents the study’s measures of manufacturing strategy variables and new
venture performance.
Manufacturing strategy variables. Respondents provided data, reflecting their venture’s ac-
tual, rather than planned (or desired), activities over the immediate past three years. Multi-
item indexes were developed to measure these activities. In each case, the average response
score was used in the analysis. Average scores were calculated by summing item scores and
then dividing the total by the number of items. All items followed a 5-point response rate,
and the phrase “This Company . . .,” as follows:
1 2 3 4 5 NA
Very True Untrue Neutral True Very True Not Applicable
This Company
Product line breadth
. . . offers a broad line of products. 1 2 3 4 5 NA
. . . produces & markets many products. 1 2 3 4 5 NA
. . . offers a wide variety of products in its product line. 1 2 3 4 5 NA
Quality
. . . stresses being a high quality producer. 1 2 3 4 5 NA
. . . competes primarily on the basis of quality. 1 2 3 4 5 NA
Product Innovation
. . . introduces many new products to the market. 1 2 3 4 5 NA
. . . introduces more new products than competitors. 1 2 3 4 5 NA
. . . is well known for introducing breakthrough-type products. 1 2 3 4 5 NA
Commercialization
. . . has reduced the time between the development and market
introduction of new products significantly. 1 2 3 4 5 NA
. . . introduces products to the market faster than the competition. 1 2 3 4 5 NA
Low Cost/Low Price
. . . pursues market leadership by being a low cost producer. 1 2 3 4 5 NA
. . . charges higher prices than those of competitors (reverse scored). 1 2 3 4 5 NA
. . . stresses charging the lowest prices in the market. 1 2 3 4 5 NA
Capital Spending
. . . emphasizes capital spending more than major competitors. 1 2 3 4 5 NA
. . . spends more than the industry average on new plants. 1 2 3 4 5 NA
. . . has first rate manufacturing facilities. 1 2 3 4 5 NA
Vertical Integration
. . . distributes products directly to customers. 1 2 3 4 5 NA
. . . produces most of its raw materials internally. 1 2 3 4 5 NA
. . . is vertically integrated 1 2 3 4 5 NA
Sourcing
. . . has many suppliers. 1 2 3 4 5 NA
. . . develops its products internally (reverse). 1 2 3 4 5 NA
. . . contracts out a major portion of its R&D activities. 1 2 3 4 5 NA
(continued)
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(Continued)
New Venture Performance (NVP). Executives provided data for a 3-year period on growth
in sales and growth in market share. These measures are explained in the text. Because data
were gathered through the survey—a common practice in the literature—validation of the
performance figures was necessary. Thus, data were collected for a subset of companies,
using annual reports and trade publications. When annual reports were used, only data on
the particular CVs were included. Secondary and survey data were then correlated, as follows:
sales growth (r 5 .71, n 5 23) and market share growth (r 5 .66, n 5 19).
A third performance measure (6 items, a 5 .85) was developed to gauge managers’
perceptions of their new venture’s performance. Two evaluations, per item, were used. The
first indicated the importance of each item (the “importance” score). The second indicated
the extent top managers were satisfied with the unit’s performance of each items (the
“satisfaction” score). Importance scores were multiplied by their corresponding satisfaction
scores. The sum was then divided by 6 (the number of items in the scale).
How Important is this How Satisfied are you with the
goal for your company company’s achievement of the goal
Very Very
Unimportant Important Dissatisfied Satisfied
Return on 1 2 3 4 5 1 2 3 4 5
investment
Return on 1 2 3 4 5 1 2 3 4 5
equity
Sales growth 1 2 3 4 5 1 2 3 4 5
Net profit 1 2 3 4 5 1 2 3 4 5
margin
Market share 1 2 3 4 5 1 2 3 4 5
Return on 1 2 3 4 5 1 2 3 4 5
assets
New Ventures’ Innovative Output: Emphasis on Patenting (3 items, a 5 .78). Pilot interviews
indicated that companies were unwilling to provide data on their patenting activities. Hence,
a multi-item index measured a venture’s emphasis on patenting. The index was then correlated
with patent applications or actual counts for a subset of 41 ventures (r 5 .53, n 5 41, p , .01).
In addition, the index significantly correlated with the actual number of patents obtained
by 71 firms in the sample (r 5 .61, p , .001). The patenting measure used in the study was
as follows:
1 2 3 4 5 NA
Very True Untrue Neutral True Very True Not Applicable
This Company
*. . . holds important patent rights 1 2 3 4 5 NA
*. . . has more patents than its key competitors 1 2 3 4 5 NA
*. . . has increased its patenting efforts over the past 3 years 1 2 3 4 5 NA
Pilot interviews indicated that companies were unwilling to provide data on their patenting
activities. Hence, a multi-item index measured a venture’s emphasis on patenting. The index
was then correlated with patent applications or actual counts for a subset of 41 ventures
(r 5 .53, n 5 41, p , .01).
